Laromustine
- Generic Name
- Laromustine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14ClN3O5S2
- CAS Number
- 173424-77-6
- Unique Ingredient Identifier
- 14J2G0U3NQ
- Background
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
- Indication
Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), colorectal cancer, leukemia (lymphoid), leukemia (myeloid), lung cancer, myelodysplastic syndrome, pediatric indications, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 135
- Registration Number
- NCT00840684
- Locations
- π«π·
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00521859
- Locations
- πΊπΈ
UT MD Anderson Cancer Center, Houston, Texas, United States
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
- Conditions
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2011-08-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 14
- Registration Number
- NCT00516282
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
πΊπΈHematology-Oncology Associates of Illinois, Chicago, Illinois, United States
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT00354276
- Locations
- π«π·
Hopital Haut Leveque, Pessac, France
πΊπΈJonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
π¬π§University Hospital of Wales, Cardiff, Wales, United Kingdom
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00304005
- Locations
- πΊπΈ
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT00282022
- Locations
- πΊπΈ
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
πΊπΈCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
πΊπΈKimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 420
- Registration Number
- NCT00112554
- Locations
- πΊπΈ
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
πΊπΈDana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈRiverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
- Conditions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 42
- Registration Number
- NCT00098761
- Locations
- πΊπΈ
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
πΊπΈUCSF Comprehensive Cancer Center, San Francisco, California, United States
πΊπΈDuke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00098436
- Locations
- πΊπΈ
American Health Network - North Illinois Street, Indianapolis, Indiana, United States
πΊπΈCase Comprehensive Cancer Center, Cleveland, Ohio, United States
πΊπΈDuke Comprehensive Cancer Center, Durham, North Carolina, United States
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
- Conditions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT00083187
- Locations
- πΊπΈ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
π«π·Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
π¬π§King's College Hospital, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.